Literature DB >> 16954232

Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen.

A Sauerbrei1, P Wutzler.   

Abstract

Since the introduction of varicella vaccination in several countries, there has been an urgent need for commercially available test procedures that allow highly sensitive and specific quantitative determination of the varicella-zoster virus (VZV)-specific immune status, including immunity postimmunization. This study compared the performance of two enzyme-linked immunosorbent assays (ELISAs) for the sensitive and specific determination of VZV-specific immunoglobulin G (IgG) in seronegative and latently infected persons, as well as in vaccinees. One ELISA is based on the detection of antibody to VZV-specific envelope glycoproteins (gp), and the other comprises the whole antigen extract prepared from VZV-infected cells. A modified standard fluorescent-antibody-to-membrane-antigen (FAMA) assay was used as a reference. An excellent sensitivity (100%) in relation to FAMA was demonstrated for the gpELISA (Virion\Serion), while the non-gpELISA (Dade Behring) had a lower sensitivity (83%) when sera from latently infected persons were tested. After postvaccinal immunity was measured, a sensitivity of 87% was achieved with gpELISA, whereas the ELISA incorporating antigen extract of VZV-infected cells had a sensitivity of 78%. Excellent specificity (100%) was calculated for both the gpELISA and the non-gpELISA. In conclusion, SERION ELISA classic VZV IgG is useful for the sensitive and specific quantitative determination of VZV immune status after natural infection. The test can also be recommended for measuring antibody response after varicella vaccination, particularly after the cutoff value was optimized.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16954232      PMCID: PMC1594709          DOI: 10.1128/JCM.00719-06

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  Virological diagnosis of herpes simplex encephalitis.

Authors:  A Sauerbrei; U Eichhorn; G Hottenrott; P Wutzler
Journal:  J Clin Virol       Date:  2000-06       Impact factor: 3.168

2.  An advisory committee statement (ACS). National Advisory Committee on Immunization (NACI). NACI update to statement on varicella vaccine.

Authors: 
Journal:  Can Commun Dis Rep       Date:  2002-02-15

3.  Comparison of gpELISA and neutralizing antibody responses to Oka/Merck live varicella vaccine (Varivax) in children and adults.

Authors:  D L Krah; I Cho; T Schofield; R W Ellis
Journal:  Vaccine       Date:  1997-01       Impact factor: 3.641

Review 4.  Assays for antibodies to varicella-zoster virus.

Authors:  D L Krah
Journal:  Infect Dis Clin North Am       Date:  1996-09       Impact factor: 5.982

5.  Comparison of two methods for detecting varicella-zoster virus antibody with varicella-zoster virus cell-mediated immunity.

Authors:  A Weinberg; A R Hayward; H B Masters; I A Ogu; M J Levin
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

6.  Seroprevalence of varicella-zoster virus in the German population.

Authors:  P Wutzler; I Färber; S Wagenpfeil; H Bisanz; A Tischer
Journal:  Vaccine       Date:  2001-10-12       Impact factor: 3.641

7.  Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers.

Authors:  L Saiman; P LaRussa; S P Steinberg; J Zhou; K Baron; S Whittier; P Della-Latta; A A Gershon
Journal:  Infect Control Hosp Epidemiol       Date:  2001-05       Impact factor: 3.254

8.  Live varicella vaccine in both immunocompromised and healthy children.

Authors:  M E Morales-Castillo; M T Alvarez-Muñoz; F Solórzano-Santos; R González-Robledo; L Jasso-Gutiérrez; O Muñoz-Hernández
Journal:  Arch Med Res       Date:  2000 Jan-Feb       Impact factor: 2.235

9.  Susceptibility to varicella zoster virus infection in health care workers.

Authors:  J Gallagher; B Quaid; B Cryan
Journal:  Occup Med (Lond)       Date:  1996-08       Impact factor: 1.611

10.  Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay.

Authors:  P A C Maple; J Gray; J Breuer; G Kafatos; S Parker; D Brown
Journal:  Clin Vaccine Immunol       Date:  2006-02
View more
  19 in total

1.  Uptrend prevalence of varicella parallel with low serum antibodies and low second-dose rate among children 10-14 years old in Wenzhou, China.

Authors:  Qi Liu; Jiake Yu; Jingjiao Wei; Hu Zhang; Jie Jin; Weikun Zheng; Yufei Ruan; Jinsheng Yu; Yiping Chen
Journal:  Hum Vaccin Immunother       Date:  2020-07-02       Impact factor: 3.452

2.  Safety and immunogenicity of Bio Pox™, a live varicella vaccine (Oka strain) in Indian children: A comparative multicentric, randomized phase II/III clinical trial.

Authors:  Anand Prakash Dubey; Mohammad Moonis Akbar Faridi; Monjori Mitra; Iqbal Rajinder Kaur; Aashima Dabas; Jaydeep Choudhury; Mallar Mukherjee; Devendra Mishra
Journal:  Hum Vaccin Immunother       Date:  2017-05-16       Impact factor: 3.452

Review 3.  Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections.

Authors:  A Sauerbrei
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-02-12       Impact factor: 3.267

4.  Secretion of truncated recombinant rabies virus glycoprotein with preserved antigenic properties using a co-expression system in Hansenula polymorpha.

Authors:  Weidong Qian; Frank Aguilar; Ting Wang; Bingsheng Qiu
Journal:  J Microbiol       Date:  2013-04-27       Impact factor: 3.422

5.  Vaccine-related varicella-zoster rash in a hospitalized immunocompetent patient.

Authors:  Paul Bernstein; Yoko Furuya; Sharon Steinberg; Brian Scully; Philip Larussa; Anne A Gershon
Journal:  Am J Infect Control       Date:  2011-01-26       Impact factor: 2.918

6.  Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test.

Authors:  Andreas Sauerbrei; Anna Schäfler; Jörg Hofmann; Michael Schacke; Bernd Gruhn; Peter Wutzler
Journal:  Clin Vaccine Immunol       Date:  2012-06-20

7.  Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.

Authors:  Ann M Arvin; Jerry S Wolinsky; Ludwig Kappos; Michele I Morris; Anthony T Reder; Carlo Tornatore; Anne Gershon; Michael Gershon; Myron J Levin; Mauritz Bezuidenhoudt; Norman Putzki
Journal:  JAMA Neurol       Date:  2015-01       Impact factor: 18.302

Review 8.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

9.  A systematic approach for the identification of novel, serologically reactive recombinant Varicella-Zoster Virus (VZV) antigens.

Authors:  Maria G Vizoso Pinto; Klaus-Ingmar Pfrepper; Tobias Janke; Christina Noelting; Michaela Sander; Angelika Lueking; Juergen Haas; Hans Nitschko; Gundula Jaeger; Armin Baiker
Journal:  Virol J       Date:  2010-07-20       Impact factor: 4.099

10.  Evaluation of a commercial glycoprotein enzyme-linked immunosorbent assay for measuring vaccine immunity to varicella.

Authors:  Yun Hwa Kim; Ji Young Hwang; Hye Min Shim; Eunsil Lee; Songyong Park; Hosun Park
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.